Author:
McLellan B.,Ciardiello F.,Lacouture M.E.,Segaert S.,Van Cutsem E.
Funder
Bayer HealthCare Pharmaceuticals
Succinct Medical Communications
Reference84 articles.
1. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;Wilhelm;Int J Cancer,2011
2. Regorafenib (BAY 73–4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer;Schmieder;Int J Cancer,2014
3. A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors;Mross;Clin Cancer Res,2012
4. Regorafenib (BAY 73–4506) in advanced colorectal cancer: a phase I study;Strumberg;Br J Cancer,2012
5. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics;Sunakawa;Invest New Drugs,2014
Cited by
113 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献